Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Unmet needs in immunotherapy for neoadjuvant and adjuvant settings in MIBC

Richard Cathomas • 31 May 2026
ASCO 2026
Bladder Cancer Genitourinary Cancer

Richard Cathomas, MD, Cantonal Hospital Graubunden, Chur, Switzerland, briefly discusses ongoing challenges surrounding the use of immunotherapy in the neoadjuvant and adjuvant settings for muscle-invasive bladder cancer (MIBC). Dr Cathomas highlights the need for reliable biomarkers, the potential role of circulating tumor DNA (ctDNA) in guiding treatment decisions, and the possibility of eliminating adjuvant therapy in selected patients. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Richard Cathomas

Integrating recombinant BCG in the perioperative treatment landscape for MIBC
1:27
Integrating recombinant BCG in the perioperative treatment landscape for MIBC
Richard Cathomas • 31 May 2026
SAAK 06/19: intravesical recombinant BCG plus chemo-IO in MIBC
0:59
SAAK 06/19: intravesical recombinant BCG plus chemo-IO in MIBC
Richard Cathomas • 31 May 2026
Bladder-sparing approaches in muscle-invasive urothelial carcinoma
0:37
Bladder-sparing approaches in muscle-invasive urothelial carcinoma
Richard Cathomas • 5 Jun 2022
EV-302: 1L enfortumab vedotin in combination with pembrolizumab
0:35
EV-302: 1L enfortumab vedotin in combination with pembrolizumab
Richard Cathomas • 5 Jun 2022

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals